Business Wire

NTHU

22.9.2022 11:01:35 CEST | Business Wire | Press release

Share
Tsing Hua University Hospital Preparatory Office Officially Opens in Taoyuan

On August 20, the Tsing Hua University Hospital Preparatory Office was officially opened in the Xinkong Building at the Taoyuan Metro Corporation’s Qingpu Depot, which is only one MRT station away from the site where the Hospital will be built.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005421/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

At the opening ceremony (right to left): NTHU senior vice presidents Tai Nyan-hwa and Lyu Ping-chiang, NTHU president W. John Kao, Taoyuan City mayor Cheng Wen-tsan, former NTHU president Hocheng Hong, Taoyuan Metro chairman Liu Kun-I, and Taoyuan Aerotropolis chairman Chen Si-jhen. (Photo: National Tsing Hua University)

NTHU and the Taoyuan City Government have already signed a letter of intent outlining their plan to jointly establish a world-class medical center that will serve the local community; the plan also includes assistance in the training of bilingual teachers and support for science education and experimental education at Taoyuan’s kindergartens, primary, and secondary schools.

The Preparatory Office was officially inaugurated by Taoyuan City mayor Cheng Wen-tsan and NTHU president W. John Kao.

Mayor Cheng has played a key role in the early stages of the Hospital project. He pointed out that Taiwan is good at both electronics and medical care, both of which are taught at NTHU, and that’s why he has been such a staunch supporter of NTHU through all the difficulties which have arisen in the planning stage.

Cheng emphasized that it will take only ten minutes for an ambulance to go from the Taoyuan International Airport to the emergency room at the new hospital; and that in addition to cosmetic surgery and health examinations, the Hospital will also provide critical care and boron neutron capture therapy (BNCT).

Moreover, the Hospital is expected to become a leading center for the development of advanced cell regeneration technology.

President Kao said that this is a very important day for NTHU, in that the school has long had its sights set on medical education, and now the dream has finally come true, noting that “Today is a new milestone in this 50-kilometer journey from NTHU to Taoyuan, which has been going on for some 66 years.”

Kao also noted that this year could be seen as the “year of medicine” at NTHU, since the first batch of medical students has recently been enrolled.

The Hospital will be located near the Hengshan Station (A16) of the Airport MRT line, on a parcel of land provided by Taoyuan City. The size of the parcel is 7.2 hectares, of which 5 hectares will be used for the Hospital itself, while the remaining 2.2 hectares will be used for the affiliated teaching and research facilities.

NTHU senior vice president Lyu Ping-chiang said that the BOT agreement will be finalized by the end of this year, and that construction will start next year, soon after the parcel is transferred. The Hospital is expected to be completed by the end of 2027 and opened in 2028.

The Hospital will initially have 200 general acute care beds, plus an intensive care unit, a respiratory care unit, negative pressure isolation rooms, and a psychiatric unit for both inpatients and outpatients, all of which will be gradually expanded over a number of years to reach a total capacity of 910 beds.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005421/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye